SCHEMBL29381891

SCHEMBL29381891

O=S(=O)(O)c1cccc2cccc(Nc3ccccc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 1.00
TTR P02766 1/20 1.00
CCNA2 P20248 1/20 1.00
CDK2 P24941 1/20 1.00
MAPK14 Q16539 1/20 1.00
NR4A1 P22736 1/20 0.97
SNCA P37840 3/20 0.67
CHAT P28329 1/20 0.67
FABP1 P07148 1/20 0.62
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
THRB P10828 1/20 0.52
MAPT P10636 3/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51
RECQL P46063 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
NSD2 O96028 2/20 0.51
CASP6 P55212 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43158 1.00 FABP4 (1.00) FABP4TTRCCNA2CDK2MAPK14
Ammonia Solution, Strong SCHEMBL592279 0.98 NR4A1 (1.00) FABP4TTRCCNA2CDK2MAPK14
Ammonia Solution, Strong SCHEMBL592280 0.98 NR4A1 (1.00) FABP4TTRCCNA2CDK2MAPK14
SCHEMBL6654772 0.98 FABP4 (0.97) FABP4TTRCCNA2CDK2MAPK14
SCHEMBL10353163 0.98 FABP4 (0.97) FABP4TTRCCNA2CDK2MAPK14
SCHEMBL1786500 0.98 FABP4 (0.97) FABP4TTRCCNA2CDK2MAPK14
Ammonia Solution, Strong SCHEMBL31666356 0.97 NR4A1 (0.97) FABP4TTRCCNA2CDK2MAPK14
SCHEMBL7522280 0.92 FABP4 (0.84) FABP4TTRCCNA2CDK2MAPK14
SCHEMBL29837420 0.92 CDK2 (0.84) FABP4TTRCCNA2CDK2MAPK14
Questiomycin B SCHEMBL20817145 0.88 TTR (0.78) FABP4TTRCCNA2CDK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102332-A1 NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF Blaze Bioscience, Inc. (US) 2026-05-15 WO claimed
EP-4694868-A1 PROTEIN PARTICLES AND METHODS OF MAKING AND USING THE SAME Dairy Management Inc. (US) 2026-02-18 EP claimed
EP-4586911-A1 LUMINESCENT ENZYME-BASED SENSORS Terumo Cardiovascular Systems Corporation (US) 2025-07-23 EP claimed
WO-2025123135-A1 ASSAY FOR DETECTION AND QUANTIFICATION OF PFAS COMPOUNDS FREDSENSE TECHNOLOGIES CORP. (CA) 2025-06-19 WO claimed
EP-4536933-A1 FLUORESCENT METAL-ORGANIC FRAMEWORKS Saudi Arabian Oil Company (SA) 2025-04-16 EP claimed
WO-2024216002-A1 PROTEIN PARTICLES AND METHODS OF MAKING AND USING THE SAME Dairy Management Inc. (US) 2024-10-17 WO claimed
EP-4427033-A1 METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA Biotech GmbH (DE) 2024-09-11 EP claimed
CN-117969472-A Method for high-throughput determination of heat stability and iron saturation of lactoferrin 陕西科技大学 2024-05-03 CN claimed
WO-2024059143-A1 LUMINESCENT ENZYME-BASED SENSORS TERUMO CARDIOVASCULAR SYSTEMS CORPORATION (US) 2024-03-21 WO claimed
WO-2023239252-A1 FLUORESCENT METAL-ORGANIC FRAMEWORKS SAUDI ARABIAN OIL COMPANY (SA) 2023-12-14 WO claimed
WO-2023079052-A1 METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF PROTEIN AGGREGATES PAIA BIOTECH GMBH (DE) 2023-05-11 WO claimed
EP-4076500-A1 METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS Blaze Bioscience, Inc. (US) 2022-10-26 EP claimed
EP-3948262-A1 METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS Bristol-Myers Squibb Company (US) 2022-02-09 EP claimed
EP-4747264-A1 MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE University of Reading (GB) 2026-05-27 EP disclosed
WO-2026105126-A1 DNA-BASED MECHANOSENSITIVE DELIVERY AGENTS AND USES THEREOF TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2026-05-21 WO disclosed
WO-2026102332-A1 NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF Blaze Bioscience, Inc. (US) 2026-05-15 WO disclosed
US-11278556-B2 Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs NATIONAL JEWISH HEALTH (US) 2022-03-22 US disclosed
EP-3947438-A1 STABILIZED MHC I imusyn GmbH & Co. KG (DE) 2022-02-09 EP disclosed
EP-3946256-A1 HUMAN PAPILLOMAVIRUS NANOPARTICLE FORMULATIONS Aura Biosciences, Inc. (US) 2022-02-09 EP disclosed
EP-3948262-A1 METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS Bristol-Myers Squibb Company (US) 2022-02-09 EP disclosed